Vanda pharmaceuticals inc. (VNDA)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
Net product sales

227,188

193,118

165,083

146,017

109,925

12,909

-

0

-

5,290

1,979

Royalty revenue

-

-

-

-

-

6,502

7,090

5,938

4,481

3,141

-

Licensing agreement

-

-

-

-

-

30,746

26,789

26,789

26,789

26,789

2,569

Total revenues

227,188

193,118

165,083

146,017

109,925

50,157

33,879

32,727

31,270

35,709

4,548

Grant revenue

-

-

-

-

-

-

-

-

-

489

-

Operating expenses:
Cost of goods sold excluding amortization

24,488

20,508

17,848

24,712

23,462

1,583

-

129

-

2,891

1,915

Research and development

48,649

43,594

38,547

29,156

29,145

19,230

28,502

45,764

28,996

12,338

13,874

Selling, general and administrative

129,736

105,751

123,841

99,787

84,531

84,644

25,082

14,517

11,486

10,147

23,724

Intangible asset amortization

1,505

1,527

1,750

10,933

12,972

2,254

1,495

1,495

1,495

1,495

983

Gain on arbitration settlement

-

-

-

-

-

77,616

-

-

-

-

-

Total operating expenses

204,378

171,380

181,986

164,588

150,110

30,095

55,079

61,905

41,977

26,871

40,496

Loss from operations

22,810

21,738

-16,903

-18,571

-40,185

20,062

-21,200

-29,178

-10,707

8,838

-35,948

Other income

6,218

3,608

1,472

665

320

124

145

561

461

431

89

Income (loss) before income taxes

29,028

25,346

-15,431

-17,906

-39,865

20,186

-

-

-10,246

9,269

-35,859

Income Tax Expense (Benefit)

-86,525

138

136

100

-

0

-

-

-444

2,077

-

Net Income (Loss) Attributable to Parent

115,553

25,208

-15,567

-18,010

-39,865

20,186

-21,055

-28,617

-9,802

7,192

-35,859

Earnings Per Share [Abstract]
Basic (in dollars per share)

2.17

0.50

-0.35

-0.41

-0.94

0.58

-0.69

-1.01

-0.35

0.26

-1.33

Diluted (in dollars per share)

2.11

0.48

-0.35

-0.41

-0.94

0.55

-0.69

-1.01

-0.35

0.25

-1.33

Weighted average shares outstanding:
Basic (in shares)

53,137

50,859

44,735

43,449

42,250

34,774

30,351

28,228

28,106

27,916

27,015

Diluted (in shares)

54,847

53,045

44,735

43,449

42,250

36,686

30,351

28,228

28,106

28,534

27,015